Breaking Down GT Biopharma, Inc. (GTBP) Financial Health: Key Insights for Investors

Are you keeping a close watch on biotech innovators? Ever wonder how clinical-stage companies navigate the financial maze while pioneering cancer treatments? Let’s dissect GT Biopharma Inc. (NASDAQ: GTBP), a firm focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform. As of September 30, 2024, the company reported approximately $6.5 million in cash and cash equivalents, expected to sustain operations into Q2 2025. With a recent analyst consensus pointing to a 'Strong Buy' and an ambitious $11.00 price target, is GT Biopharma a promising investment or a high-stakes gamble? Dive in as we explore their financial standing, R&D expenditures, and market potential, offering you key insights to inform your investment decisions.

GT Biopharma, Inc. (GTBP) Revenue Analysis

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies based on its proprietary NK cell engager, TriKE® and TetraKE™ platforms. As a clinical-stage company, GT Biopharma's financial performance is characterized by substantial research and development expenses and the absence of significant product revenue.

Given its status as a clinical-stage biopharmaceutical company, GT Biopharma, Inc. primarily relies on funding from sources other than product sales to sustain its operations. These sources typically include:

• Equity Financing: GT Biopharma may issue and sell shares of its stock to raise capital.
• Debt Financing: The company may borrow money through loans or the issuance of bonds.
• Grants and Government Funding: GT Biopharma may receive grants from government agencies or non-profit organizations to support specific research projects.
• Partnerships and Licensing Agreements: Collaborations with other companies can provide upfront payments, milestone payments, and royalties on future sales of partnered products.

As of the fiscal year 2024, GT Biopharma, Inc. has not generated substantial revenue from product sales. The company's financial statements primarily reflect:

• Operating Expenses: These include research and development (R&D) expenses, clinical trial costs, and general and administrative (G&A) expenses.
• Other Income/Expenses: This may include interest income, gains or losses on investments, and other non-operating items.

For detailed financial information, investors and interested parties should consult GT Biopharma's filings with the Securities and Exchange Commission (SEC). These filings, including annual reports (Form 10-K) and quarterly reports (Form 10-Q), provide comprehensive information on the company's financial condition and results of operations.

Here is a general overview of key financial aspects for GT Biopharma, understanding that specific figures can fluctuate:

For more in-depth insights, read this comprehensive analysis: Breaking Down GT Biopharma, Inc. (GTBP) Financial Health: Key Insights for Investors

GT Biopharma, Inc. (GTBP) Profitability Metrics

Analyzing GT Biopharma, Inc. (GTBP)'s profitability involves examining several key metrics that provide insights into the company's financial health. These include gross profit, operating profit, and net profit margins, as well as trends in these areas over time. Comparing these ratios with industry averages and assessing operational efficiency are crucial for investors.

As the latest 2024 fiscal year data is not yet available, the following analysis is based on the information available up to the present date.

GT Biopharma, Inc. (GTBP) has faced challenges regarding profitability, as reflected in its financial results. For instance, the company's financial statements indicate a history of net losses. Reviewing the trends in profitability over the past few years provides a clearer picture of the company's ability to manage costs and generate profit.

Here's a breakdown of key areas to consider:

• Gross Profit: This is the revenue remaining after deducting the cost of goods sold (COGS). Monitoring trends in gross profit helps to understand how efficiently GT Biopharma, Inc. (GTBP) manages its production costs.
• Operating Profit: This metric is calculated by deducting operating expenses from gross profit. It reflects the profitability of the company's core business operations.
• Net Profit: Net profit is what remains after all expenses, including interest and taxes, are deducted from total revenue. The net profit margin, calculated as net profit divided by total revenue, indicates the percentage of revenue that translates into profit.

To provide a clearer picture, a comparison of GT Biopharma, Inc. (GTBP)'s profitability ratios with industry averages can offer valuable context. However, without specific 2024 data, it's essential to refer to the latest available financial reports and industry benchmarks for accurate comparisons.

Operational efficiency is also a critical factor. Analyzing how well GT Biopharma, Inc. (GTBP) manages its costs and the trends in its gross margin can reveal insights into its operational effectiveness. For example, a rising gross margin suggests improved cost management and pricing strategies.

For more in-depth information, you can explore: Breaking Down GT Biopharma, Inc. (GTBP) Financial Health: Key Insights for Investors

GT Biopharma, Inc. (GTBP) Debt vs. Equity Structure

Understanding how GT Biopharma, Inc. (GTBP) finances its operations is crucial for investors. This involves examining the company's debt levels, debt-to-equity ratio, and recent financing activities to assess its financial leverage and stability.

As of the fiscal year 2024, detailed information on GT Biopharma, Inc.'s (GTBP) debt levels, specifically the amounts of long-term and short-term debt, is not readily available in the provided search results. Investors would typically find this information in the company's annual reports (10-K) or quarterly reports (10-Q) filed with the Securities and Exchange Commission (SEC). These reports provide a comprehensive overview of the company's financial position, including its liabilities.

Similarly, the exact debt-to-equity ratio for GT Biopharma, Inc. (GTBP) as of 2024 cannot be calculated without the specific debt and equity figures from their financial statements. The debt-to-equity ratio is a key metric used to evaluate a company's financial leverage. It is calculated by dividing total liabilities by total equity. A higher ratio indicates that the company is financing a greater proportion of its assets with debt, which can increase financial risk. The company’s debt-to-equity ratio should be compared to industry standards to determine whether it is in line with its peers or if it is an outlier, which could signal potential concerns.

Information regarding recent debt issuances, credit ratings, or refinancing activities for GT Biopharma, Inc. (GTBP) in 2024 is not available within the search results. Significant financial events like these can have a material impact on a company's financial structure and should be monitored closely by investors. Credit ratings, if available, would provide an assessment of the company's creditworthiness and ability to repay its debts.

The balance between debt and equity financing is a strategic decision for GT Biopharma, Inc. (GTBP). While debt financing can provide capital for growth without diluting ownership, it also introduces fixed interest payments and the risk of default. Equity financing, on the other hand, does not require repayment but dilutes existing shareholders' ownership. How GT Biopharma, Inc. (GTBP) manages this balance is a reflection of its financial strategy and risk tolerance.

For detailed financial information, refer to GT Biopharma, Inc.'s (GTBP) official filings with the SEC and recent investor presentations.

Here is more information: Breaking Down GT Biopharma, Inc. (GTBP) Financial Health: Key Insights for Investors

GT Biopharma, Inc. (GTBP) Liquidity and Solvency

Liquidity is crucial for assessing a company's ability to meet its short-term obligations. For GT Biopharma, Inc. (GTBP), evaluating the current and quick ratios, working capital trends, and cash flow statements provides insights into its financial health.

Current and Quick Ratios: These ratios measure a company's ability to pay off its short-term liabilities with its short-term assets. The current ratio is calculated by dividing current assets by current liabilities, while the quick ratio excludes inventories from current assets, offering a more conservative view. As of the end of fiscal year 2024, need to consult financial data to determine the exact figures and assess GT Biopharma's liquidity position. Generally, a current ratio of 1.5 to 2.0 and a quick ratio of 1.0 or higher are considered healthy, but these benchmarks can vary by industry.

Working Capital Trends: Monitoring working capital trends—the difference between current assets and current liabilities—helps to understand the company's operational efficiency and short-term financial health. An increasing working capital balance typically indicates improved liquidity, while a decreasing balance may signal potential challenges in meeting short-term obligations. Analysis of GT Biopharma's working capital over the past few years would provide a clearer picture of its liquidity management.

Cash Flow Statements Overview: A review of GT Biopharma's cash flow statements, focusing on operating, investing, and financing activities, is essential. Analyzing these cash flow trends helps to understand how the company generates and uses cash. Here's a brief look at what each section reveals:

• Operating Activities: This section shows the cash generated from the company's core business operations. Positive cash flow from operations is a healthy sign, indicating that the company is generating enough cash to cover its operating expenses.
• Investing Activities: This includes cash flow related to the purchase and sale of long-term assets, such as property, plant, and equipment (PP&E). Negative cash flow in this section might indicate investments in growth, while positive cash flow could be from asset sales.
• Financing Activities: This section covers cash flow related to debt, equity, and dividends. It shows how the company is raising capital and returning it to investors.

By examining these components, investors can gain a comprehensive understanding of GT Biopharma’s cash management and its ability to fund its operations and growth.

Potential Liquidity Concerns or Strengths: A thorough analysis of these financial metrics is necessary to identify any potential liquidity concerns or strengths. For instance:

• If GT Biopharma has a low current or quick ratio, it may struggle to meet its short-term obligations.
• Consistently negative cash flow from operations could indicate underlying issues with the company's business model.
• Effective management of working capital and positive trends in cash flow from operations would be positive indicators of financial health.

For more insights into GT Biopharma's mission, vision, and core values, you can visit Mission Statement, Vision, & Core Values of GT Biopharma, Inc. (GTBP).

GT Biopharma, Inc. (GTBP) Valuation Analysis

Determining whether GT Biopharma, Inc. (GTBP) is overvalued or undervalued requires a look at several key financial metrics. Here’s a breakdown to help investors assess the company’s valuation:

Valuation Ratios:

• Price-to-Earnings (P/E) Ratio: The P/E ratio for GT Biopharma is -14.62. A negative P/E ratio suggests that the company is currently not profitable.
• Price-to-Book (P/B) Ratio: GT Biopharma's P/B ratio is 1.37. This indicates how much investors are paying for each dollar of the company's book value.
• Enterprise Value-to-EBITDA (EV/EBITDA): The EV/EBITDA ratio is -8.45. Like the negative P/E ratio, a negative EV/EBITDA can indicate financial distress or that the company's earnings are negative.

Stock Price Trends:

• The stock price has experienced significant volatility over the past 12 months.
• 52-week Low: $1.72.
• 52-week High: $10.66.
• As of April 17, 2025, the stock price was around $2.27.
• Price volatility: 68.9%.

Dividend Yield and Payout Ratios:

• Dividend Yield: GT Biopharma does not pay dividends.
• Payout Ratio: Not applicable as the company does not distribute dividends.

Analyst Consensus:

• The analyst consensus on GT Biopharma stock is a Moderate Buy.
• Based on 1 Wall Street analyst, the 12-month average price target is $11.00.
• Recommendation:
  • Buy: 33.3%
  • Hold: 50%
  • Sell: 16.7%

Additional Factors:

Here's a look at additional financial performance indicators for GT Biopharma, Inc. (GTBP):

Given these metrics, investors should carefully consider GT Biopharma's lack of current profitability and high volatility. Analyst ratings suggest some optimism, but a thorough understanding of the company's financial health and future prospects is essential. To gain more insight into the company's values, consider reading about Mission Statement, Vision, & Core Values of GT Biopharma, Inc. (GTBP).

GT Biopharma, Inc. (GTBP) Risk Factors

GT Biopharma, Inc. (GTBP) faces a variety of risks that could significantly impact its financial health. These risks span internal operational challenges and external market forces. Understanding these factors is crucial for investors assessing the company's prospects. For more insights, you might want to check out Mission Statement, Vision, & Core Values of GT Biopharma, Inc. (GTBP).

Here's a breakdown of key risks:

• Industry Competition: The biotechnology industry is intensely competitive. GT Biopharma faces competition from larger, more established companies with greater financial and technical resources. This competition can affect the company's ability to successfully develop, commercialize, and market its products.
• Regulatory Changes: The development and marketing of biopharmaceutical products are subject to extensive regulation by government authorities, including the FDA in the United States. Changes in regulatory requirements or delays in obtaining regulatory approvals can significantly impact GT Biopharma’s timelines and increase costs.
• Market Conditions: Unfavorable market conditions, such as economic downturns or changes in investor sentiment towards the biotechnology industry, can affect GT Biopharma’s ability to raise capital and maintain its stock price.

Operational, financial, and strategic risks can be gleaned from recent earnings reports and filings. These documents often highlight specific challenges the company is addressing.

Some potential risks include:

• Clinical Trial Risks: The success of GT Biopharma depends heavily on the outcomes of its clinical trials. Unfavorable or inconclusive results can lead to significant delays, increased costs, and the potential failure of product candidates.
• Manufacturing Risks: Manufacturing biopharmaceutical products is complex and subject to strict quality control requirements. Any disruptions in manufacturing processes or failures to meet quality standards can impact GT Biopharma’s ability to supply its products.
• Intellectual Property Risks: Protecting its intellectual property is crucial for GT Biopharma. Challenges to its patents or other intellectual property rights can weaken its competitive position.
• Financial Risks: GT Biopharma needs sufficient capital to fund its research and development activities. The inability to secure additional funding when needed could force the company to delay or abandon its programs.

Mitigation strategies are plans that GT Biopharma may implement to address these risks. These strategies can include:

• Diversifying Product Pipeline: Developing multiple product candidates can reduce the company’s reliance on any single product.
• Strategic Alliances: Partnering with other companies can provide access to additional resources, expertise, and funding.
• Risk Management Programs: Implementing comprehensive risk management programs can help identify, assess, and mitigate potential risks.

Below is a hypothetical table summarizing potential risks and mitigation strategies (note that this is an example and should be verified with actual company filings):

It is important for investors to carefully review GT Biopharma's filings with the Securities and Exchange Commission (SEC), including its annual reports on Form 10-K and quarterly reports on Form 10-Q, to obtain a comprehensive understanding of the risks the company faces and its plans to mitigate them.

GT Biopharma, Inc. (GTBP) Growth Opportunities

For GT Biopharma, Inc. (GTBP), several factors could drive future growth. These include product innovations, strategic market expansions, potential acquisitions, and the establishment of key partnerships. By capitalizing on these areas, GT Biopharma, Inc. (GTBP) aims to enhance its market position and financial performance.

GT Biopharma, Inc. (GTBP) is focusing its efforts on:

• Product Innovations: Advancing the development of its TriKE™ technology platform to create novel cancer therapies.
• Market Expansion: Exploring opportunities to expand its clinical trials and eventual commercialization into new geographic markets.
• Strategic Partnerships: Collaborating with other biotechnology and pharmaceutical companies to accelerate the development and commercialization of its products.

These initiatives are aimed at strengthening GT Biopharma, Inc. (GTBP)'s competitive edge and driving revenue growth.

While specific revenue growth projections and earnings estimates for GT Biopharma, Inc. (GTBP) are not available, several strategic initiatives and partnerships could significantly influence its future growth trajectory. These include:

• Advancement of GT Biopharma, Inc. (GTBP)'s TriKE™ Technology: Progressing clinical trials for various TriKE™ candidates, which could lead to significant revenue upon regulatory approval and commercialization.
• Partnerships and Collaborations: Forming strategic alliances with other companies to expand the development and marketing of its therapies.
• Expansion into New Indications: Exploring the use of TriKE™ technology in additional cancer types, broadening the potential market for its products.

GT Biopharma, Inc. (GTBP)'s competitive advantages include its proprietary TriKE™ technology platform, which has the potential to revolutionize cancer treatment. The company's focus on developing novel immunotherapies and its strategic partnerships also position it favorably for future growth. However, GT Biopharma, Inc. (GTBP) faces competition from other biotechnology and pharmaceutical companies developing cancer therapies.

More information about GT Biopharma, Inc. (GTBP)'s financial health can be found at: Breaking Down GT Biopharma, Inc. (GTBP) Financial Health: Key Insights for Investors